Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Impedimed Limited ( (AU:IPD) ) has issued an update.
ImpediMed Limited has disclosed a change in the holdings of director Andrew Grant, who received 100,563 new ordinary shares, increasing his direct interest to 2,973,309 shares. The shares were issued on 14 January 2026 in lieu of 15% of his director fees for the quarter ended 31 December 2025, indicating the company’s continued use of equity-based remuneration to align director incentives with shareholder interests; no trades occurred during a closed period, and there were no changes to any director-related contracts.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.07 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
ImpediMed Limited is a medical technology company listed on the ASX, focused on developing and commercialising bioimpedance spectroscopy devices and related solutions for the assessment and management of fluid status and body composition, particularly in clinical settings such as oncology and heart failure. Its products target healthcare providers and institutions seeking objective, non-invasive tools for diagnosing and monitoring conditions associated with fluid imbalances.
Average Trading Volume: 1,179,706
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$71.34M
For a thorough assessment of IPD stock, go to TipRanks’ Stock Analysis page.